Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloi... ( CHICAGO June 3 2011 /- Cornerstone ...)

HOME >> MEDICINE >> TECHNOLOGY

Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia

Date:6/3/2011

CHICAGO, June 3, 2011 /PRNewswire/ -- Cornerstone Pharmaceuticals and Wake Forest Baptist Medical Center today announced key findings from a Phase I clinical trial of Cornerstone's first-in-class cancer metabolism inhibitor drug, CPI-613 in Acute Myeloid Leukemia (AML). Data will be presented at the 47th Annual meeting of American Society of Clinical Oncology (ASCO): http://www.chicago2011.asco.org/. Cornerstone is a leader in the discovery and development of cancer therapies based on the science of cancer metabolism.

CPI-613 is being studied at Wake Forest Baptist's Comprehensive Cancer Center to evaluate safety, tolerability, maximum tolerated dose, efficacy, and pharmacokinetics for patients with relapsed and refractory hematologic malignancies. The novel agent, CPI-613, has activity against several acute leukemia cell lines and may have activity in patients with relapsed disease. The mode of cytotoxicity and degree of synergy with more traditional agents remains a focus of ongoing study.

"This study is important because relatively few treatment options exist for patients with AML," said CEO Cornerstone Pharmaceuticals, Robert Shorr, Ph.D. "Preliminary results from the ongoing Phase I study demonstrate the safety of first-in-class agent, CPI-613, with very few adverse events, and support further exploration of CPI-613 as a potential treatment for AML and other hematologic malignancies."

According to the National Cancer Institute, 1 in 77 men and women will be diagnosed with leukemia during their lifetime. It is estimated that of the 43,050 Americans diagnosed annually, 21,840 of those will die of leukemia in 2011. Chemotherapy is the standard of treatment for untreated adult

SOURCE Cornerstone Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
3. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
4. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
5. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
6. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
7. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
8. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
9. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
10. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
11. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia

Post Your Comments:

(Date:6/18/2013)... , June 18, 2013 Decision Resources, ... firms for pharmaceutical and healthcare issues, announces that ... of the Middle East ... Tracker analyzes the challenges and opportunities to gaining ... international regions comprising 24 countries. The countries covered ...

(Date:6/18/2013)... , June 18, 2013 New-generation ... being highly portable and lightweight. Simultaneously, circuitry is ... the processing speed to which it performs at. ... medical electronics and military equipment, such as cameras ... Omnetics, micro-circular and nano-circular connectors include custom cable ...

(Date:6/18/2013)... And EMERYVILLE, Calif. , June ... final results today from a Phase 2/3 clinical ... demonstrating a statistically significant improvement in levodopa-induced dyskinesia ... week 8 versus placebo in the Unified Dyskinesia ... formulation of amantadine intended for once-nightly administration that ...

Breaking Medicine Technology:Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 2 Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 3 Omnetics Circular Connectors Offer Both Micro and Nano Interconnects for Highly Portable Electronic Systems, Meeting the Needs of Designers Looking for Size Reduction Options and Cable Flexibility 2 Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 2 Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 3 Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 4 Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 5 Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 6

[0] Decision Resources' Market Access Tracker Now Covers the Middle East and Africa [0] Omnetics Circular Connectors Offer Both Micro and Nano Interconnects for Highly Portable Electronic Systems, Meeting the Needs of Designers Looking for Size Reduction Options and Cable Flexibility [0] Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease

... Therapeutics, Inc. (NASDAQ: ECTE ), a company ... wireless, transdermal continuous glucose monitoring system and its Prelude® ... Patrick T. Mooney, M.D., Chairman & CEO of Echo ... Conference. Dr. Mooney will make a presentation ...

... Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today ... operating officer, is scheduled to present a company overview ... York City on Wednesday, December 14th at 1:00 p.m. ... ) To access the live audio webcast ...

Cached Medicine Technology:

Echo Therapeutics to Present at the Oppenheimer Healthcare Conference Rigel to Present at Oppenheimer Annual Healthcare Conference

(Date:6/19/2013)... Mesothelioma Victims Center says, "According to the ... citizens, who will be diagnosed with a rare form ... will be US Navy Veterans. We can assure a ... of cancer, or their family members that we will ... mesothelioma compensation settlement attorneys, who actually do have a ...

(Date:6/19/2013)... Faith4Kidz is starting a new fundraising effrt ... would like help showing support for kids to learn how ... positive. Check out the website, http://www.gracenfaith.com to see ... red, white and blue stars as a symbol of our ... as well as the stars we should encourage our children ...

(Date:6/18/2013)... Exposed Skin Care has finally been released after much ... ages finally achieve the clear, beautiful skin they have always ... clearing system combines the power of science and nature to ... , After a quick review of Exposed ... the most effective available on the market to cure acne ...

(Date:6/18/2013)... South Africa (PRWEB) June 19, 2013 Looking ... disillusionment and monotony of everyday life? , IWALKAWAKE is ... awakening process. Written by Adam Botha, it focuses on harnessing ... , The book lays out a nine-step guide to ... a process that a person must go through to reach ...

(Date:6/18/2013)... York (PRWEB) June 19, 2013 The ... understanding and unprecedented access to the drug delivery partnering ... healthcare companies. , The report provides a detailed ... drug delivery partnering deals. The majority of deals are ... right or an option right to license the license ...

Breaking Medicine News(10 mins):Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation 2 Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation 3 Health News:Faith4Kidz Introduces Patriotic Hats to Benefit the "Grace in Faith Equals Peace" Mission 2 Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 2 Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 3 Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 2 Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 3 Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 4

[0] Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation [0] Faith4Kidz Introduces Patriotic Hats to Benefit the "Grace in Faith Equals Peace" Mission [0] Exposed Skin Care Review Released by ExposedSkinCareReview.org [0] Learn How To Stop Sleepwalking Through Life in New Book 'IWALKAWAKE'[0] New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz

... The Institute for Health Freedom (IHF) is warning the ... government to plan for each American to use "an" ... or patient-consent provisions."Congress needs to add opt-out and patient-consent ... IHF president. "The bottom line is that if YOU ...

... Full Value,Committee announced today that it has filed ... materials and is commencing,distribution of those soliciting materials ... ) ("LCAV") to solicit consents to replace the ... highly qualified nominees. The Full,Value Committee,s director ...

... 9 Team Health Inc.,s,parent company, Team Finance LLC ... fiscal year and the fourth quarter ended,December 31, 2008. ... for uncollectibles ("revenue less provision"),for the fiscal year ended ... billion in the prior year. Same contract revenue less ...

... Powerful opioid drugs can pose risks even for patients, ... The U.S. Food and Drug Administration announced plans Monday ... painkillers by requiring manufacturers of certain opioid drugs to ... with the medications. , The FDA said it has ...

... genes can be used to reliably identify the four ... at Washington University School of Medicine in St. Louis ... potentially predict the most effective therapy for each breast ... all patients., "Unlike a widely used genomic test that ...

... adolescent use of prescription pain relievers has dropped, report ... of prescription painkillers among young adults increased from 4.1 ... government report released Monday shows. , However, the researchers ... (SAMHSA) also found that non-medical use of painkillers by ...

Economic Stimulus Bill Mandates Electronic Health Records for Every American by 2014 - With No Opt-out Provision The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders Team Finance LLC Announces Fiscal 2008 Financial Results FDA Seeks Better Regulation of Painkillers New genomic test can personalize breast cancer treatment Painkiller Abuse Increases Among Young Adults

Lacrimal Cannula, Curved - Open End, 21gSize: 21g x 1-1/2"....

PremierEdge™ Implant Knives....

Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...

Medicine Products:

Lacrimal Cannula, Curved - Open End.PremierEdge™ Implant Knives Universal I/A handpiece - Titanium (Binkhorst Tip)Universal I/A handpiece - Titanium (Curved Tip, Size: 16g Outer Cannula)